skip to main content

brainstorm askiatroX medicines

simulations beta

loading page…

learn & practise

exams international doctors free questions Socratic Tutor rounds stat clinical connections academy journal tool guides

clinical reference

askiatroX knowledge centre medicines UK / NICE guidance international guidance calculators q&a library

trust & support

how it works methodology account & support frequently asked questions about us clinical safety consultancy

legal

mobile app · scan to download

Medicines mepolizumabQuestion & answer

mepolizumab · Medicine question

What is the contraindication to mepolizumab treatment?

iatroX medicinesPublished 8 November 2026

The answer

Answer

Mepolizumab (Nucala) is contraindicated in patients with hypersensitivity to mepolizumab or any of the excipients listed in section 6.1.

Sources for this answer

Nucala 100 mg solution for injection in pre-filled penGlaxoSmithKline UK · emc · SmPC §4.3 Contraindications · Version 11Document updated 12 January 2026

Sources checked 8 November 2026

Explore this learning need in CPDTake this topic to CPD, then choose your learning context and available question library.

The full medicine guide

More questions about mepolizumab

For which adults is Nucala (mepolizumab) indicated as add-on maintenance treatment for COPD?From what age is Nucala (mepolizumab) indicated as add-on treatment for severe refractory eosinophilic asthma?Can Nucala (mepolizumab) 100 mg solution for injection in a pre-filled pen be mixed with other medicines?Does Nucala (mepolizumab) affect the ability to drive or use machines?Has mepolizumab been studied in patients with organ-threatening or life-threatening eosinophilic granulomatosis with polyangiitis (EGPA)?

mepolizumab

Read the wider context, including uses, precautions and the sources behind this medicine guide.

Read the mepolizumab guide

More clinical questions?

Explore the tools and reference material available on iatroX.

Explore askiatroX

How does mepolizumab prevent interleukin-5 (IL-5) from activating its receptor?